Literature DB >> 23312632

Epidemiology of neurologically disabling disorders.

Alan Tennant1.   

Abstract

Neurological disorders place a considerable burden upon individuals, their families, and society. Some like stroke are common, while others like amyotrophic lateral sclerosis are much rarer. Some conditions such as multiple sclerosis are reported to vary by latitude, while others such as traumatic brain injury can vary considerably by locality. Depending upon the nature of the lesion, and factors such as time since onset, the consequences to the individual may also vary considerably, not just among different disorders, but within a given disorder. Consequently the patterns of disease incidence, its prevalence, and its consequences are complex and may vary not just because of the condition itself, but also because, for example, case ascertainment may vary from study to study. The cumulative annual incidence of disabling neurological disorders is likely to exceed 1000 per 100000, or 1% of the population. The incidence is characterized by significant variation, which is mediated by genetic, geographical, demographic, and environmental factors. While useful comparisons can be made through standardization techniques, planning for local services should be based upon local epidemiology, whenever available.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23312632     DOI: 10.1016/B978-0-444-52901-5.00007-1

Source DB:  PubMed          Journal:  Handb Clin Neurol        ISSN: 0072-9752


  8 in total

Review 1.  The meningeal lymphatic vessels and the glymphatic system: Potential therapeutic targets in neurological disorders.

Authors:  Gaowei Li; Yi Cao; Xin Tang; Jianhan Huang; Linjun Cai; Liangxue Zhou
Journal:  J Cereb Blood Flow Metab       Date:  2022-04-28       Impact factor: 6.960

2.  CCR5 Is a Therapeutic Target for Recovery after Stroke and Traumatic Brain Injury.

Authors:  Mary T Joy; Einor Ben Assayag; Dalia Shabashov-Stone; Sigal Liraz-Zaltsman; Jose Mazzitelli; Marcela Arenas; Nora Abduljawad; Efrat Kliper; Amos D Korczyn; Nikita S Thareja; Efrat L Kesner; Miou Zhou; Shan Huang; Tawnie K Silva; Noomi Katz; Natan M Bornstein; Alcino J Silva; Esther Shohami; S Thomas Carmichael
Journal:  Cell       Date:  2019-02-21       Impact factor: 66.850

3.  Preliminary study on patients located at the Kashani/Isfahan Hospital with multiple sclerosis between the years 2011 and 2013.

Authors:  Zahra Tolou-Ghamari; Fereshteh Ashtari; Vahid Shaygannejad; Abbas-Ali Palizban
Journal:  Adv Biomed Res       Date:  2015-08-10

4.  Preliminary study related the incidence of methylprednisolone pulse therapy in patients visited multiple sclerosis clinic located at the isfahan kashani hospital.

Authors:  Zahra Tolou-Ghamari; Vahid Shaygannejad; Fereshteh Ashtari
Journal:  Int J Prev Med       Date:  2013-05

5.  What is the Real Fate of Vitamin D in Multiple Sclerosis?

Authors:  Vahid Shaygannejad; Zahra Tolou-Ghamari
Journal:  Int J Prev Med       Date:  2013-05

6.  Study of type a and B behavior patterns in patients with multiple sclerosis in an Iranian population.

Authors:  Vahid Shaygannejad; Sedigheh Rezaei Dehnavi; Fereshteh Ashtari; Somayeh Karimi; Leila Dehghani; Rokhsareh Meamar; Zahra Tolou-Ghamari
Journal:  Int J Prev Med       Date:  2013-05

7.  Effect of disease duration on personality type in multiple sclerosis patients and healthy individual.

Authors:  Sahar Vesal; Leila Dehghani; Masoud Etemadifar; Elahe Poorazizi; Sima Akhavan; Samaneh Mazrouei; Nasim Mehdizadeh; Zahra Saraf
Journal:  Adv Biomed Res       Date:  2016-03-16

8.  Geospatial Analysis of Environmental Atmospheric Risk Factors in Neurodegenerative Diseases: A Systematic Review.

Authors:  Mariana Oliveira; André Padrão; André Ramalho; Mariana Lobo; Ana Cláudia Teodoro; Hernâni Gonçalves; Alberto Freitas
Journal:  Int J Environ Res Public Health       Date:  2020-11-13       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.